Augmenix Raises Cash

Luke Timmerman7/23/09

Augmenix, a Waltham, MA-based medical device developer, has raised $4.7 million out of an equity round potentially worth $7.5 million, according to a regulatory filing. The company is attempting to develop the first synthetic material to put space between tissues, so that radiation treatments for prostate cancer don’t damage healthy tissue nearby, according to the company’s website.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.